Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | GRM7 | Q14831 | 3/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13035557 | 0.80 | EPHX2 (0.41) | FASNMTNR1AMTNR1BGRM7 | |
| SCHEMBL16252563 | 0.80 | FASN (0.36) | FASNMTNR1AMTNR1BGRM7SMYD3 | |
| SCHEMBL15199663 | 0.80 | FASN (0.36) | FASNMTNR1AMTNR1BGRM7SMYD3 | |
| SCHEMBL12207205 | 0.80 | FASN (0.36) | FASNMTNR1AMTNR1BGRM7SMYD3 | |
| SCHEMBL12206769 | 0.80 | FASN (0.36) | FASNMTNR1AMTNR1BGRM7SMYD3 | |
| SCHEMBL25560389 | 0.78 | FASN (0.41) | FASNMTNR1AMTNR1BGRM7SMYD3 | |
| SCHEMBL22916971 | 0.78 | ATM (0.48) | FASNMTNR1AMTNR1BATM | |
| SCHEMBL23570706 | 0.78 | SMYD3 (0.30) | SMYD3 | |
| SCHEMBL24758066 | 0.78 | FASN (0.39) | FASNMTNR1AMTNR1BPKM | |
| SCHEMBL23571003 | 0.78 | FASN (0.39) | FASNMTNR1AMTNR1BPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022263573-A1 | ISOXAZOLINE PESTICIDES | ELANCO TIERGESUNDHEIT AG (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20210188789-A1 | ISOXAZOLINE DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188789-A1 | ISOXAZOLINE DERIVATIVES | CYP3A7, CYP4X1, SIRT7 | IDO1 72/4885FASN 2672/4885MTNR1A 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.